2016 American Transplant Congress
A Sustained Viral Response Achieved with Sofosbuvir/Ledipasvir May Increase the Incidence of Acute Cellular Rejection Post Liver Transplantation.
Transplant Surgery, New York University Langone Medical Center, New York, NY.
Acute cellular rejection following liver transplantation has decreased in incidence with the use of potent immunosuppressive agents, affecting less than 25 percent of liver transplantation…2016 American Transplant Congress
Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV).
Aurora St Luke's Medical Center, Milwaukee, WI.
Background: Current guidelines recommend newer therapies over previous interferon-based treatments. The creation of a specialty pharmacy program within our institution that provides managed care for…2016 American Transplant Congress
Induction Immunosuppression and Post-Transplant Outcomes in Kidney Recipients with Hepatitis C Virus.
Kidney transplantation is a well-established treatment option for ESRD patients with Hepatitis C virus (HCV). However, the optimal induction regimen for this population is uncertain,…2016 American Transplant Congress
HCV, Acute Rejection, and the New Direct-Acting Antivirals in Deceased Donor Kidney Transplant Recipients.
The association between hepatitis C virus (HCV) seropositivity and acute rejection (AR) in kidney transplant donors and recipients is unclear, and may have changed with…2016 American Transplant Congress
Initial Experience Treating Hepatitis C Positive Kidney Transplant Recipients with Non-Interferon-Containing Regimens: Successes and Challenges.
Weill Cornell Medical College, New York, NY.
Historically, treatment of hepatitis C virus (HCV) infection with interferon-based regimens after kidney transplantation has been associated with risk of rejection & graft loss. Direct…2016 American Transplant Congress
Utilization and Post-Transplant Outcomes Associated with Hepatitis C+ Donor Kidneys in the Advent of Direct-Acting Antivirals.
The introduction of interferon-free direct-acting antivirals(DAAs) in December 2013 dramatically improved outcomes for individuals with Hepatitis C. The impacts of these therapies on utilization and…2016 American Transplant Congress
Outcomes of Ribavirin Free Treatment of Recurrent Genotype 1 , Hepatitis C Infection Post Liver Transplant.
Background. With the development of direct-acting antivirals, the treatment of Hepatitis C Virus (HCV) has become a rapidly changing area of medical practice. Data on…2016 American Transplant Congress
The Use of Sofosbuvir (SOF)-Containing Direct Antiviral Agents (DAA)-Based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection.
Background: The use of SOF-containing regimens based on NS5A inhibitors has not been shown interactions with Tac in liver transplant.Specific data on KT recipients are…2016 American Transplant Congress
Superior Waitlist and Equivalent Transplant Outcomes Among Hepatitis C RNA-Positive Patients Who Are Willing to Accept Hepatitis C Seropositive Kidneys.
Background: kidney transplantation from hepatitis C seropositive (HCV+) donors may benefit hepatitis C RNA-positive (RNA+) candidates, but it is not clear how the acceptance/listing status…2016 American Transplant Congress
Evaluation of Long Term Outcome After Living Donor Liver Transplantation in Sequential 653 Recipients with or without Viral Infection: Is HBV & HCV Co-Infection Better Than the Monoinfection? A Single Center Retrospective Analysis.
Organ Transplantation, China Medical University Hospital, Taichung, Taiwan.
Background:End-stage liver disease secondary to HBV and HCV coinfection is not uncommon in Asia.However,long term outcome of such patients after living donor liver transplantation (LDLT)…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 28
- Next Page »